Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia

High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective...

ver descrição completa

Detalhes bibliográficos
Autores: Ribera, Jose-Maria|||0000-0003-1042-6024, Morgades, Mireia|||0000-0003-0295-2534, Garcia-Calduch, Olga, Sirvent, Maialen, Buendia, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernández Rivas, Jesús María|||0000-0002-9661-9371, Sitges, Marta|||0000-0003-1300-4732, García Cadenas, Irene|||0000-0002-2994-9055, Abrisqueta, Pau|||0000-0001-9625-7422, Montesinos, Pau|||0000-0002-3275-5593, Bastos, Mariana|||0000-0002-9431-4646, Queipo de Llano, María Paz, Bravo, Pilar, Torrent Catarineu, Anna|||0000-0002-3727-5716, Herrera, Pilar|||0000-0002-4118-7110, Garcia Guiñón, Antoni, Vall-Llovera, Ferran|||0000-0002-0718-5955, Serrano, Josefina, Terol, Maria José, Bergua Burgues, Juan Miguel|||0000-0001-8229-1208, Garcia-Noblejas, Ana, Barrenetxea, Cristina|||0000-0002-9777-8788, Llorente, Laura, Garcia-Belmonte, Daniel|||0000-0002-0353-3457, Gimeno, Eva|||0000-0002-3534-6189, Cladera, Antonia, Mercadal, Santiago|||0000-0003-4741-7885, Sancho, Juan-Manuel|||0000-0001-7168-6538
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:289760
Acesso em linha:https://ddd.uab.cat/record/289760
https://dx.doi.org/urn:doi:10.3324/haematol.2023.283342
Access Level:acceso abierto
Palavra-chave:Aged
Antineoplastic Combined Chemotherapy Protocols
Burkitt Lymphoma
Cyclophosphamide
Doxorubicin
Drug Tapering
Feasibility Studies
HIV Infections
Humans
Leukemia
Middle Aged
Prospective Studies
Rituximab
Young Adult
Descrição
Resumo:High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients.

Registos relacionados